Drug discovery remains one of the most expensive and time-intensive processes in the pharmaceutical industry. Traditional approaches rely on sequential, siloed teams and limited computational screening, often taking years and costing hundreds of millions of francs to bring a single candidate to clinical trials. Leading Swiss pharma and biotech companies are now deploying sovereign multi-agent AI research teams that work collaboratively and autonomously to explore chemical spaces, analyse medical literature, predict molecular interactions, and prioritise promising candidates — all while keeping every piece of sensitive research data securely on Swiss infrastructure.
- Drug discovery timelines accelerated by 40–70% in early stages
- Multi-agent collaboration enables exploration of vastly larger chemical spaces
- Full EU AI Act compliance and complete data residency on Exoscale SKS
- Higher-quality candidates with better predicted success rates
- Research teams reclaim significant time through autonomous literature analysis and hypothesis generation
The Bottlenecks in Traditional Drug Discovery
The conventional drug discovery pipeline is linear and slow. Scientists manually review literature, screen compounds sequentially, and iterate hypotheses over months or years. This approach limits exploration and increases the risk of missing promising candidates.
The Sovereign Multi-Agent Research Team Solution
A new paradigm is emerging: sovereign multi-agent AI research teams. These autonomous systems coordinate multiple specialised agents that work in parallel, continuously learning from each other and from new data — all running inside dedicated Swiss tenants on Exoscale SKS.
How the Multi-Agent Research System Works
Built with LangGraph orchestration, the solution coordinates specialised agents:
• Literature & Knowledge Agent – continuously analyses millions of papers using sovereign RAG
• Molecular Design & Simulation Agent – generates and evaluates novel compounds in silico
• Predictive Biology Agent – forecasts efficacy, toxicity, and mechanism of action
• Hypothesis & Prioritisation Agent – ranks candidates and suggests next experiments
The entire team operates with full auditability and zero data leaving Swiss borders.
Proven Results from Swiss Life Sciences Companies
Early deployments have delivered impressive outcomes:
• Early-stage discovery timelines shortened by 40–70%
• Number of viable candidates increased significantly
• Research costs reduced through smarter prioritisation
• Full EU AI Act compliance with explainable AI outputs
• Faster progression of high-potential molecules into preclinical development
Why Sovereignty Is Critical for Drug Discovery
Drug discovery data includes highly sensitive intellectual property, proprietary molecular designs, and patient-related information. Foreign cloud solutions cannot meet the strict data residency and regulatory control requirements that Swiss pharma companies must satisfy. Sovereign multi-agent platforms deliver both breakthrough speed and full Swiss control.
